Cinclus Pharma Holding AB
Clinical-stage pharma developing a next-gen P-CAB drug for severe GERD patients.
CINPHA | ST
Overview
Corporate Details
- ISIN(s):
- SE0020388577
- LEI:
- 549300TJBPSNZ3DO6B42
- Country:
- Sweden
- Address:
- Kungsbron 1, Plan 3, trappa G, 111 22 Stockholm
- Website:
- https://cincluspharma.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Cinclus Pharma Holding AB is a clinical-stage pharmaceutical company focused on developing advanced treatments for gastric acid-related diseases. The company's lead drug candidate, linaprazan glurate, is a novel Potassium-Competitive Acid Blocker (P-CAB) engineered to address the unmet medical needs of patients with Gastroesophageal Reflux Disease (GERD), especially those inadequately treated by conventional Proton Pump Inhibitors (PPIs). Positioned as a next-generation therapy, linaprazan glurate aims to deliver superior clinical efficacy and an improved pharmacokinetic profile for sustained acid control. Having successfully completed Phase II clinical trials, Cinclus Pharma is working to register and commercialize its lead asset globally, with the goal of creating a paradigm shift in the management of acid-related conditions.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-11-18 08:00 |
Regulatory News Service
Cinclus Pharma's Nomination Committee for the 2026 Annual General Meeting appoi…
|
English | 79.1 KB | ||
| 2025-11-18 08:00 |
Regulatory News Service
Cinclus Pharmas Valberedning för årsstämma 2026 utsedd
|
Swedish | 78.9 KB | ||
| 2025-08-29 07:30 |
Regulatory News Service
Cinclus Pharma inleder fas III-studien HEEALING 1 med linaprazan glurate för pa…
|
Swedish | 89.5 KB | ||
| 2025-08-29 07:30 |
Legal Proceedings Report
Cinclus Pharma to initiate HEEALING 1 Phase III study of linaprazan glurate in …
|
English | 88.4 KB | ||
| 2025-08-20 08:00 |
Interim Report
|
Swedish | 2.6 MB | ||
| 2025-08-20 08:00 |
Interim Report
|
English | 2.8 MB | ||
| 2025-05-22 20:12 |
Post-Annual General Meeting Information
Beslut vid årsstämma i Cinclus Pharma Holding AB (publ) den 22 maj 2025
|
Swedish | 79.8 KB | ||
| 2025-05-22 20:12 |
Post-Annual General Meeting Information
Resolutions at the Annual General Meeting in Cinclus Pharma Holding AB (publ) o…
|
English | 81.2 KB | ||
| 2025-05-22 07:30 |
M&A Activity
Cinclus Pharma ingår partnerskap med Zentiva för att kommersialisera linaprazan…
|
Swedish | 93.4 KB | ||
| 2025-05-22 07:30 |
M&A Activity
Cinclus Pharma Partners with Zentiva to Commercialize Linaprazan Glurate in Eur…
|
English | 92.2 KB | ||
| 2025-05-20 08:00 |
Quarterly Report
|
Swedish | 2.5 MB | ||
| 2025-05-20 08:00 |
Quarterly Report
|
English | 2.6 MB | ||
| 2025-04-30 16:00 |
Annual Report (ESEF)
|
Swedish | 29.7 MB | ||
| 2025-04-30 16:00 |
Annual Report (ESEF)
|
Swedish | 29.7 MB | ||
| 2025-02-20 08:00 |
Annual Report
|
Swedish | 2.3 MB |
Automate Your Workflow. Get a real-time feed of all Cinclus Pharma Holding AB filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Cinclus Pharma Holding AB
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Cinclus Pharma Holding AB via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
